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The endothelial cell receptor complex for kininogen (HK) comprises gC1qR, cytokeratin 1,
and urokinase-type plasminogen activator receptor and is essential for activation of the
kinin system that leads to bradykinin (BK) generation. Of these, gC1qR/p33 constitutes a
high afﬁnity site for HK – the BK precursor – and is therefore critical for the assembly of
the kinin-generating cascade. Previous studies have identiﬁed a putative HK site within the
C-terminal domain (residues 204–218) of gC1qR recognized by mAb 74.5.2. In these stud-
ies, we used information from the crystal structure of gC1qR, to engineer several deletion
(Δ) mutants and test their ability to bind and/or support BK generation. While deletion of
residues 204–218 (gC1qRΔ204–218), showed signiﬁcantly reduced binding to HK, BK gen-
eration was not affected when tested by a sensitive bradykinin immunoassay. In fact, all of
the gC1qR deletion mutants supported BK generation with the exception of gC1qRΔ154–
162 and a point mutation in which Trp 233 was substituted with Gly. Binding studies also
identiﬁed the existence of two additional sites at residues 144–162 and 190–202. More-
over, binding of HK to a synthetic peptide 190–202 was inhibited by mAbs 48 and 83, but
not by mAb 74.5.2. Since a single residue separates domains 190–202 and 204–218, they
may be part of a highly stable HK binding pocket and therefore a potential target for drug
design to prevent vascular permeability and inﬂammation.
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INTRODUCTION
The surface receptor for (gC1qR) is a ubiquitously distributed,
highly anionic cellular protein of 33 kDa that binds to the globular
heads of C1q (gC1q; Ghebrehiwet et al., 1994, 2001; Ghebrehi-
wet and Peerschke, 1998). Known alternatively as p33, p32, or
hyaluronic acid binding protein 1 (HABP-1), it is a multi-ligand
binding protein that is distributed in several cellular compart-
ments, including the mitochondria, the ER, and the nucleus, in
addition to the cell surface (Ghebrehiwet et al., 1994; Dedio et al.,
1998; van Leuwen and O’Hare, 2001). It is its surface expression
and structural basis of its function that have been the primary
focus of our laboratory for the past 20 years (Ghebrehiwet et al.,
1994, 2001; Ghebrehiwet and Peerschke, 1998).
The binding of HK, to gC1qR is strictly zinc dependent (Her-
wald et al., 1996; Joseph et al., 1996; Hasan et al., 1998). HK
binds to endothelial cell (EC) surface expressed gC1qR with high
afﬁnity (K d of 9± 2 nM; Herwald et al., 1996) and to isolated
gC1qR with a K d of 0.8± 0.7 nM (kon = 12.3± 5.0× 104/M/s;
koff = 0.8± 0.5× 10−4/M/s; Pixley et al., 2011). The interaction
Abbreviations: BK, bradykinin; gC1qR, receptor for the globular heads of C1q; HK,
high molecular weight kininogen; KKS, kallikrein kinin system.
between HK and cell surface expressed or isolated gC1qR is inhib-
ited bymAb 74.5.2,which recognizes theC-terminal half of gC1qR
comprising residues 204–218 (Joseph et al., 1996). The receptors,
which are organized as two bimolecular complexes of gC1qR–
cytokeratin 1 and urokinase-type plasminogen activator receptor
(uPAR)–cytokeratin 1, are essential for the assembly and activa-
tion of the coagulation/kinin-forming cascade (Mahdi et al., 2001;
Joseph et al., 2004).
The plasma kinin-forming pathway consists of three essen-
tial proteins that interact in vivo in a complex fashion once
bound to a macromolecular complex formed during inﬂamma-
tory response or bound to proteins along cell surfaces (Kaplan,
2004). These are coagulation factor XII [FXII (or Hageman factor,
HF)], prekallikrein (PK), and high molecular weight kininogen
(HK). Once FXII is activated to FXII a, it converts prekallikrein,
which circulates as complex with HK, to kallikrein and the latter
in turn digests HK to generate the nonapeptide BK (H-Arg-Pro-
Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH; Kaplan, 2004). Bradykinin,
belongs to the kinin family of proinﬂammatory peptides, and is
among the most potent vasodilator agonists known (Erdos and
Sloane, 1962; Regoli and Barabe, 1980; Bhoola et al., 1992; Mar-
golius, 1998). The afﬁnity of HK and HKa for gC1qR is much
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higher [gC1qR> cytokeratin 1> uPAR than it is for cytokeratin 1
or uPAR and thus gC1qR may be pivotal for the assembly of the
kallikrein kinin system (KKS; Herwald et al., 1996; Colman et al.,
1997)].
Mature gC1qR is extremely acidic with a calculated pI of 4.15
(Ghebrehiwet et al., 1994, 2002; Jiang et al., 1999). It has one Cys at
residue 186 and thus does not have any intrachain-disulﬁde bond-
ing. It doesnot dimerize by inter-chaindisulﬁdebonding either: on
SDS-PAGE, it migrates as a 33-kDa band under both reducing and
non-reducing conditions (Ghebrehiwet et al., 1994). However, it
behaves as a trimer on gel ﬁltration in non-dissociating conditions
(Ghebrehiwet et al., 1994) and evidence from our laboratory sug-
gests that multimer formation is an essential process that increases
the afﬁnity of gC1qR for multivalent ligands such as C1q and HK
(Ghebrehiwet and Peerschke, 1998; Ghebrehiwet et al., 2001). The
non-covalent trimeric structure has since been conﬁrmed byX-ray
crystallography (Jiang et al., 1999), which reveals a donut-shaped
quaternary structure with asymmetric charge distribution (Ghe-
brehiwet et al., 1996) with one side containing a high distribution
of negatively charged residues and,whichwe refer to as the solution
face (S face), and the other side containing a more or less neutral
net charge and referred to as the membrane face (M-face; Ghe-
brehiwet et al., 2002). More importantly, the 3D structure of the
molecule reveals the presence of several highly charged domains
with potential to play a role in ligand binding and cell attachment
(Jiang et al., 1999; Ghebrehiwet et al., 2002). Using this knowl-
edge, we generated several gC1qR deletion mutants in order to
conﬁrm the previously identiﬁed HK binding site and/or identify
new ones. Identiﬁcation and reﬁnement of the precise interac-
tion sites between gC1qR and HK in turn will allow us to translate
this knowledge into novel small molecule-based, peptide-based, or
antibody-based diagnostic and/or therapeutic strategies to block
the generation of bradykinin and other vasoactive molecules that
have been shown to contribute signiﬁcantly to inﬂammatory
diseases, vascular permeability, and edema (Bossi et al., 2009).
MATERIALS AND METHODS
CHEMICALS AND REAGENTS
The following reagents and chemicals were purchased or obtained
from the sources indicated:Dulbecco’s PBS (DPBS)with andwith-
out calciumandmagnesium (Mediatech Inc.,Manassas,VA,USA);
Dulbecco’s modiﬁed Eagles medium (DMEM); RPMI 1640, 100×
Penicillin/Streptomycin, (GIBCO, Invitrogen, Grand Island, NY,
USA); heat inactivated fetal bovine serum (FBS; Hyclone, Logan,
UT, USA); human serum albumin (HSA; Immuno-US, Rochester,
MI, USA); p-nitrophenyl phosphate (pNPP; Pierce, Rockford, IL,
USA); and Immu-Mount (Thermo Fisher, Waltham, MA, USA).
Alexa-488- or Alexa-594-Streptavidin, Alexa-488- or Alexa-594-
F(ab′)2, goat anti-mouse or anti-rabbit; FITC conjugated goat
anti-mouse IgG F(ab′)2 or sheep anti-rabbit IgG F(ab′)2 (Invit-
rogen, Carlsbad, CA, USA); and alkaline phosphatase (AP) – con-
jugated rabbit anti-goat IgG (Pierce), andC4d-EIA test kit (Quidel,
San Diego, CA, USA).
EXPRESSION OF RECOMBINANT gC1qR/p33
The strategy for the construction of a plasmid containing the
full-length (mature form or wild type, WT) or truncated forms
of gC1qR cDNA as well as puriﬁcation of the glutathione-S-
transferase (GST)–gC1qR fusion products has been described in
detail in our earlier publication (Ghebrehiwet et al., 1994; Lim
et al., 1996). The GST–gC1qR fusion products were then cleaved
by thrombin (3.2μg/ml) and the GST-free gC1qR proteins puri-
ﬁed on fast protein liquid chromatography (FPLC, Pharmacia)
using a Mono-Q ion exchange column. The single peak containing
the gC1qR was pooled, concentrated to 1–2 mg/ml, and stored at
−80˚C in the presence of 50 nM PPACK (d-phenylalanyl-l-prolyl-
l-arginine chloromethyl ketone) – a speciﬁc thrombin inhibitor
(Sigma Aldrich).
GENERATION AND PURIFICATION OF DELETION gC1qR MUTANTS
The cDNA and amino acid sequences of the region of gC1qR to be
mutated, were identiﬁed and selected from analysis of the crystal
structure as described (Jiang et al., 1999; Ghebrehiwet et al., 2002).
To generate deletions, the Stratagene QuikChange double-strand
mutagenesis kit was used, using complementary sense and anti-
sense primers that bridge the deleted region (Ghebrehiwet et al.,
1994; Lim et al., 1996). Maximization of mutagenesis was achieved
by bringing the melting temperature (TM) on each side of the
deleted sequence to 60˚C as described (Breslauer et al., 1986).
Primers were extended using the PfuTurbo polymerase and the
Stratagene kit, and mutant constructs were enriched by digestion
of the methylated template with Dpn1, and transformed into E.
coli. Final constructs were sequenced in all cases to verify sequence
integrity. The fusion products were puriﬁed as described above
and elsewhere (Ghebrehiwet et al., 1994; Lim et al., 1996).
SINGLE POINT MUTAGENESIS
A single residue mutation was performed on Trp 233, which is
the only domain that projects conspicuously from the S face in
the crystal structure, fairly close to the second anionic loop as
described earlier (Ghebrehiwet et al., 2002). Encoded by the codon
TGG, this residue was mutated by a single-base change to GGG
(Gly) using double-strand mutagenesis, transformed into E. coli
and the protein puriﬁed as above.
TRIMER FORMATION
To estimate the organization and integrity of each recombinant
protein, gel ﬁltration of puriﬁed gC1qR WT as well as the vari-
ous deletion mutants was carried out by analytical gel ﬁltration
on a column (1.4 cm× 30 cm) packed with Superose beads and
equilibrated in 50 mM Tris–HCl buffer, pH 7.4, containing 1 mM
EDTA in a manner similar to that described earlier (Ghebrehiwet
et al., 1994). After adjusting the ﬂow rate to 0.2 ml/min, the col-
umn was calibrated with two proteins having molecular weights
close to those for the monomeric and trimeric forms of gC1qR,
respectively. The peak elution times of these proteins – carbonic
anhydrase (29 kDa) and BSA (65 kDa) – were recorded and used as
the standard against which the elution time of each gC1qR protein
was compared.
SDS-PAGE AND WESTERN BLOT ANALYSIS
Analyses on SDS-PAGE were performed on a 1.5-mm thick slab
gels according to the method of Laemmli (1970) with samples
being run unreduced or reduced and alkylated by boiling for 5 min
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in the presence of 0.1 M dithiothreitol and 0.2 M iodoacetamide.
After electrophoresis, the gels were stained with Coomassie Bril-
liant Blue, destained, and dried. Samples for Western blot analysis
were ﬁrst run on SDS-PAGE as above then electro transferred
to polyvinyl diﬂuoride (PVDF) or nitrocellulose membranes,
blocked with 5% non-fat milk containing TBST (20 mM Tris–
HCl, 150 mM NaCl, and 0.05% Tween 20), and the bound proteins
probed with the appropriate and speciﬁc antibodies. The bound
antibodies in turn were visualized by chemiluminescence horse-
radish peroxidase-conjugated species-speciﬁc antibody followed
by reaction with 4-chloro-1-naphthol substrate.
CULTURED CELLS
Human brain microvascular endothelial cells (HBr-MIVEC) were
cultured in Microvascular Endothelial Cell Growth Medium-2
(EGM-2MV; Lonza, Walkersville, MD, USA) and contained 5%
heat inactivated FBS. Cells grown to conﬂuence on 2% gelatin
(Type B), were ﬁrst treated with 0.25% trypsin, 0.01% EDTA to
dissociate cells from the gelatin matrix by incubation (30 min,
37˚C) in 0.01 M Tris-buffered saline. The cells were then washed
and then subcultured inDMEM.Experimentswere donewith cells
between passages 3 and 15.
U937 cells were grown in RPMI 1640 containing 10%
heat inactivated (2 h 56˚C) fetal calf serum and 1% antibi-
otic antimycotic stock (100×) mixture consisting of penicillin
G (10,000 U/ml), amphotericin B (25μg/ml) and streptomycin
sulfate (10,000μg/ml), and maintained in a humidiﬁed 37˚C
incubator in an atmosphere of 95% air and 5% CO2.
PROTEINS AND ANTIBODIES
The puriﬁed proteins used in these studies were obtained from
the following commercial sources. Single-chain or two-chain high
molecular weight kininogen (HK), as well as FXII was from
(Enzyme Res., South Bend, IN, USA) and monoclonal anti-HK
(clone 115-21) and anti-FXII (clone 179)were a generous gift from
Rebecca Rowehl (Hybridoma Core Facility, Stony Brook Univer-
sity), andwere originally generated and characterized by Reddigari
and Kaplan (1989). The various monoclonal and polyclonal anti-
bodies to recombinant gC1qR used in these studies have been
described in previous publications and represent part of the anti-
gC1qR antibody databank in our laboratory (Ghebrehiwet et al.,
1996).
SOLID-PHASE MICROPLATE BINDING ASSAY
The ability of the various gC1qR proteins to bind HK was assessed
by solid-phase ELISA using microtiter plates (Nunc, CovaLink,
NH, Denmark). Because the interactants are sticky proteins, the
ELISA experiments were designed to include a measure that will
exclude interaction due to “stickiness.” Brieﬂy duplicate wells
were ﬁrst coated (30 min, room temp or O/N, 4˚C) with 100 μl
(2μg/ml) of WT or various gC1qR mutants (ΔgC1qR) or BSA in
carbonate buffer, pH 9.6 (15 mM Na2CO3 and 35 mM NaHCO3).
The unbound proteins were aspirated; the wells washed 2× with
TBST (20 mM Tris–HCl pH 7.5, 150 mM NaCl, and 0.05% Tween-
20), and the unreacted sites blocked by incubation (30 min, room
temp) with 300μl of 1% non-fat dry milk or blotto (10 mg/ml
casein in TBS, pH 8.0). After washing 2× with TBST, 100μl each
of concentrations of HK ranging from 0 to 5μg/ml in TBSZ (TBS
containing 10–50μM Zinc) were added and incubated (30 min,
room temp). The wells were then washed, 1× with TBSZ contain-
ing 0.5 M NaCl, and 2× with TBSTZ (containing 10μM Zinc).
After drying, the bound proteins were detected by sequential addi-
tion and incubation (30 min, room temp) with 100 μl of 2μg/ml
mAb anti-HK, followed by alkaline phosphatase conjugated rabbit
anti-goat or goat anti-mouse IgG and pNPP (freshly dissolved in
10% diethanolamine pH 9.5, containing 5 mM MgCl2 and 0.02%
NaN3). In experiments in which biotin-labeled HK was employed,
the ELISA was developed using alkaline phosphatase conjugated
Neutravidin followed by pNPP. The absorbance of the resulting
color development in either case was measured at 405 nm using
a VMax Kinetic plate reader (Molecular Devices, Menlo Park, CA,
USA).The experimentsweredone at least three times induplicates.
Similar protocol was used to determine the interaction between
FXII and gC1qR either with gC1qR bound to the duplicate wells
and the bound FXII detected by mAb anti-FXII or in the reverse
order in which FXII was bound to the plate and biotinylated
gC1qR mutants were bound and detected by alkaline phosphatase
conjugated Neutravidin followed by pNPP.
BRADYKININ ASSAY
The ability of gC1qR to generate bradykinin (BK) was assayed in
the following manner. Duplicate microtiter plate wells were ﬁrst
coated (30 min, 22˚C) with 1% PEG to block charged sites, then
gC1qR mutants were incubated with 100μl of a mixture (1μg/ml
each) of highly puriﬁed HK, PK in the presence of 50 μM zinc
and in the presence or absence of FXII (1μg/ml each). Samples
were incubated (30 min, 22˚C) and the protein in the samples was
precipitated with chilled ethanol, centrifuged at 10,000× g for
20 min, and the supernatant containing BK was lyophilized and
re-suspended in the assay buffer. The amount of BK in the sam-
ple was then determined using a commercial kit from Peninsula
Laboratories (Peninsula Labs, San Carlos, CA, USA).
FLOW CYTOMETRY AND IMMUNOFLUORESCENCE ANALYSES
For ﬂow cytometry, the cultured cell line, U937, was used. After
verifying cell viability by trypan blue exclusion (≥95%), the cells
(106/ml DPBS) were preincubated (30 min, 20˚C) with isotype-
matched Fc fragments, followed by incubation (60 min, 20˚C)
with either buffer alone, or gC1qR proteins (10 μg/ml). After
incubation, the cells were washed in DPBS, and further incu-
bated with a predetermined dilution of mAb anti-gC1qR followed
by another incubation with Alexa-488 conjugated and species
matched IgG. The cells were then washed, ﬁxed by suspension
in 4% paraformaldehyde and then analyzed by ﬂow cytometry.
When biotin-labeled gC1qR proteins were used, then the cells were
directly incubated with the proteins – thus obviating the blockade
with Fc fragments – and the bound gC1qR was detected using
Alexa-488 conjugated streptavidin.
Immunoﬂuorescence studies were performed on either U937
cells or cultured HBr-MIVECs. The cells were grown on cover slips
and the attached monolayer of cells reacted ﬁrst with PBS con-
taining 0.1% BSA and 1% heat inactivated human serum to block
unreacted sites, followed by incubation with biotinylated gC1qR
proteins and FITC conjugated secondary reagent as described
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above. After ﬁxing for 10 min with 3.7% (v/v) formalin, the slides
were examined by 3D imaging using deconvolution microscopy.
SOLID-PHASE BINDING TO MICROPLATE-FIXED U937 CELLS
The ability of gC1qR and its deletion mutants to bind to U937 cells
was tested using a microplate assay with ﬁxed cells as described
elsewhere (Kennet, 1984; Ghebrehiwet et al., 1996). Brieﬂy, intact
U937 cells (2× 105 cells/well) were ﬁrst attached (30 min, 22˚C)
onto poly-l-lysine (10μg/ml in PBS, pH 7.4) coated duplicate
ELISA wells. The cells were ﬁxed (30 min, 22˚C) by addition of
an equal volume of glutaraldehyde (0.5% solution in PBS), and
the unreacted sites quenched with glycine–BSA (100 mM Glycine,
0.1% BSA in PBS, pH 7.4). Then, biotinylated gC1qR or deletion
mutants ranging 0–5μg/ml were added and the bound proteins
detected by standard ELISA procedure as described.
STATISTICAL ANALYSIS
Data are presented as mean± SEM. Student’s t -tests were per-
formed using statistical software (Excel;Microsoft, Redmond,WA,
USA). A value of p = 0.05 was considered to be a signiﬁcant dif-
ference (n values represent separate experiments performed under
the same conditions).
RESULTS
ASSESSMENT OF TRIMER FORMATION
After puriﬁcation to homogeneity as assessed by SDS-PAGE, the
deletion proteins were subjected to analytical gel ﬁltration to assess
whether deletion of a particular domain affects the trimer forma-
tion.As shown inTable 1, three deletionmutants failed tomaintain
the trimeric structure of the molecule. These domains correspond
to amino acid residues 74–95, 204–218, and 212–223. The N-
terminal residues 74–95 are part of the αA coiled-coil region of
each monomer, which forms extensive intermolecular contacts in
the trimeric structure of themolecule (Jiang et al., 1999;Ghebrehi-
wet et al., 2002). The domain covered by residues 204–218, on the
other hand, forms the bulk of the β6 structure of each monomer
with residues 212–223 essentially making the entire connecting
Table 1 | Location of deleted residues and effect on trimerization.
Deleted aa (Δ) Position in 3D Trimer formation
WT gC1qR NA Yes
Δ74–95 αA coiled-coil, N-terminus No
Δ144–148 Loop β3–β4 Yes
Δ144–162 Loop β3–β4 Yes
Δ154–162 Loop β3–β4 Yes
Δ174–180 Loop β4–β5* Yes
Δ190–202 Loop β5–β6 Yes
Δ190–192 Loop β5–β6 Yes
Δ196–202 Loop β5–β6 Yes
Δ204–218 β6+ loop β6–β7 No
Δ212–223 Loop β6–β7* No
W233G αB, coiled-coil Yes
*M-face residues.
loop between the β6 and β7 and partially covers the 20-Å donut
hole of the trimer (Jiang et al., 1999; Ghebrehiwet et al., 2002).
IDENTIFICATION OF gC1qR SITES FOR HK
As shown (Figures 1A,B), deletion of the previously identiﬁed
HK site (aa 204–218) did not support HK binding. However,
additional domains, whose deletion adversely affected HK bind-
ing, were also identiﬁed. These are domains covered by residues,
74–95, 144–148, 190–192, and 196–202. Furthermore, deletion of
residues, which are critical for the trimeric integrity (Table 1) of
the gC1qRmolecule have also reducedHKbinding, indicating that
monomeric gC1qR does not bind HK efﬁciently. The relative loca-
tions of residues 144–162 (Figure 1C) and 196–2020 (Figure 1D)
in the 3D structure of the trimeric molecule are provided for visual
reference.
Since a single residue separates 196–202 and residues 204–218,
we hypothesized that this domain, together with residues 204–
218, might be part of the HK binding pocket in gC1qR. To test
this hypothesis, we generated a synthetic peptide corresponding
to residues190–202 (six residues longer) and tested its ability to
support HK binding. The results of this experiment showed that
biotinylated HK bound to the peptide in a speciﬁc and dose-
dependent manner (not shown). Further preliminary studies also
showed that the interaction of HK with peptide 190–202 was not
inhibited by mAb 74.5.2, which recognizes residues 204–218 (not
shown). This suggested that either HK binds at multiple sites
or residues 190–202 contribute residue(s) for the putative bind-
ing pocket. Using this information, we designed experiments to
screen for monoclonal antibodies that could inhibit the interac-
tion between HK and peptide 190–202. As shown in Figure 2,
binding of biotinylated HK was completely blocked by mAbs 48
and 83 but not by mAbs 69 or 73.
IDENTIFICATION OF gC1qR SITES FOR FACTOR XII
Previous experiments have shown that the binding of FXII to the
EC surface is similar to that of HK in that it has the same require-
ment for zinc for binding and can compete for the same site with
HK at comparable molar ratio (Reddigari et al., 1993). This obser-
vation led to the postulate that the two proteins may compete for
the same receptor site on ECs. Since both HK and FXII can bind
gC1qR, we examined whether they share the same or overlapping
site(s) on the molecule. As shown in Figure 3, deletion of residues
204–218, which is the major binding site for HK did not affect
the binding of FXII. However, several deletion mutants, includ-
ing those identiﬁed as potential additional sites for HK (Figure 1)
such as domains 74–95, 144–148, and 196–202 showed remark-
ably poor binding suggesting that the binding of HK and FXII
may be to an overlapping site(s) rather than an identical site
on gC1qR.
ASSEMBLY OF KALLIKREIN/KININ SYSTEM AND BK GENERATION
We have shown previously that gC1qR is capable of serving as a
platform for the assembly of the KKS (Joseph et al., 2001a). Exper-
iments were therefore designed to identify the critical site(s) for
the assembly of KKS and the generation with BK. Two domains,
whose deletion resulted in signiﬁcantly reduced BK generation,
were identiﬁed: residues 154–162, and a single point mutation
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FIGURE 1 | Binding of HK to gC1qR mutants using solid-phase
microplate assay. Duplicate wells of microtiter plates were ﬁrst coated with
100μl (2μg/ml) of wild type or gC1qR mutants (ΔgC1qR). After the unreacted
sites were blocked, concentrations of HK were added as indicated. The bound
HK was detected by sequential interaction with 2μg/ml mAb anti-HK,
followed by alkaline phosphatase conjugated goat anti-mouse IgG and pNPP.
The absorbance of the color developed at the end of the reaction was read at
405 nm using a V Max Kinetic plate reader. Each data point (A,B) is a mean of
three experiments run in duplicates and (B) represents a saturation curve of
data in (A) and the location in gC1qR of residues 144–162 (C) and 196–202
(D) is provided as a reference. The signiﬁcance of data is indicated as:
*p ≤0.05; **p ≤0.01 and ***p ≤0.001.
W233G (not shown). Residues 154–162 are part of the disordered
segment that form the connecting loop between β4 and β5 in
the monomer, whereas Trp233 projects conspicuously from the
trimeric structure and is at the beginning of the highly conserved
sequence αB coiled-coil (Table 1).
BINDING OF DELETION MUTANTS TO CELLS
Although gC1qR is a membrane-associated protein, it can
nonetheless be secreted into the pericellular milieu by infected
cells or cells undergoing active proliferation. This soluble gC1qR
can also bind to cells in a speciﬁc and dose-dependent manner
(Peterson et al., 1997). When biotinylated gC1qR proteins were
incubated with the ﬁxed cells, almost all of the deletion mutants
were able to bind to the cells with varying degrees and in a
dose-dependent manner with the exception of gC1qRΔ144–148,
gC1qRΔ174–180, gC1qRΔ190–202, and gC1qRΔ196–202, which
bound poorly, suggesting that these domains might be involved in
cell attachment (Figure 4). These results were further conﬁrmed
when the binding of the deletion mutants to intact U937 cells
in solution was tested by ﬂow cytometry (Figure 5). In addition,
we also used deconvolution microscopy to test the binding of the
deletion mutants to microvascular endothelial cells. As shown in
Figure 6, both gC1qRΔ144–148 and gC1qRΔ174–180, which is
on the M-face of the protein, had weak to almost no binding to
ECs. Therefore these domains – in particular residues 144–148
and 174–180 – may be suitable baits to identify the cell surface
molecule to which they bind.
DISCUSSION
In the absence of the 3D structure, peptide mapping, and inhibi-
tion studies were previously used to identify the binding sites for
the ligands of gC1qR including C1q and HK. The availability of a
detailed crystal structure (Jiang et al., 1999) of gC1qR (p32) pro-
vided a unique opportunity – and a much more realistic structural
platform – to design gC1qR mutations that would permit con-
ﬁrmation of previously identiﬁed sites and/or identiﬁcation new
ones. The primary structure deduced from its cDNA shows that
gC1qR is synthesized as apre-proteinof 282 residues (Ghebrehiwet
et al., 1994) whereas its crystal structure reveals a donut-shaped
homotrimer, with a 20-Å channel, which is partially covered by
the loops connecting β6 and β7 structures, thereby reducing the
channel size by half (Jiang et al., 1999). On the basis of informa-
tion derived from the 3D structure, we generated and expressed 10
gC1qR deletion mutants – with regions predicted to contain either
a membrane attachment site or ligand binding site. In addition,we
also generated one gC1qR protein with a single mutation Trp233
to Gly (W233G) – which by virtue of its conspicuous projection
from the solution face, was considered a likely target for plasma or
pathogen associated ligands (Ghebrehiwet et al., 2002). Although
the deleted domains are ostensibly quite large, they have been
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FIGURE 2 | Binding of HK to a synthetic peptide 190–202. A peptide
corresponding to residues 190–202 was synthesized and puriﬁed to ≥95%
purity. Synthetic peptide (residues 190–202) was coated (50μg/ml) onto
duplicate microtiter wells. After blocking, the peptide was incubated with
biotinylated HK in the presence or absence of mAbs. Control for
non-speciﬁc HK binding was BSA. The data (n =2) is a representative of
experiments run in duplicates and under the same conditions. The
signiﬁcance of data is indicated as: *p ≤0.05; **p ≤0.01; and ***p ≤0.001.
FIGURE 3 | Binding of biotinylated gC1qR mutants to of FXII.The
experimental procedures are essentially as described in the Legend to
Figure 1. Each data point is a mean of three experiments run in duplicates
with p values as described in the legends to Figures 1 and 2.
carefully selected, not only by reason of a likely functional role, but
also to ensure proximity of the ﬂanking residues in the native crys-
tal structure (Jiang et al., 1999;Ghebrehiwet et al., 2002). The latter
criterion is particularly important when considering the question
whether mutant proteins fold correctly (Ghebrehiwet et al., 2002).
Judging by adjacency of ﬂanking residues in the crystal structure,
all the deletions that were generated meet this requirement well.
The highly puriﬁed deletion mutant proteins were then subjected
to analysis using a battery of functional measurements includ-
ing assessment of trimerization, speciﬁc ligand binding, general
function such as bradykinin generation, which together provided
a good assessment of folding and function.
On the basis of the data presented in these studies, we make
the following conclusions. First, with the exception of Δ74–95,
Δ204–218, and Δ212–223, all deletion mutants folded properly
and formed trimers (Table 1). Interestingly, of the three that failed
to form a trimer, the two domains are ligand binding sites that
were identiﬁed earlier by peptide mapping and antibody inhi-
bition studies (Ghebrehiwet et al., 1994, 2001; Ghebrehiwet and
Peerschke, 1998). Residues 74–95 are part of the domain encoded
by exon II (residues 78–128), which contains the C1q binding
site, whereas residues 204–218 contain the HK site and are part
of the domain encoded by exon V (residues193–233) – the only
“self-standing” exon domain in the protein predicted to have nor-
mal folding (Ghebrehiwet et al., 2002). The N-terminal domain
74–95 is part of the αA coiled-coil region of each monomer, which
forms extensive intra- and inter-monomer contacts in the trimeric
structure of the molecule (Erdos and Sloane, 1962). Second, the
experiments conﬁrm that the binding site for HK is the domain
covered by 204–218. The fact that mAb74.5.2, which inhibit HK
binding failed (not shown) to also bind to gC1qRΔ204–218
mutant further substantiates this conclusion. However, in addi-
tion to residues 204–218, we also found that residues 190–192
and 196–202 to be critical for HK binding since deletion of these
residues failed to support its binding. Furthermore, HK was able
to bind to a synthetic peptide corresponding to residues 190–
202 and this binding was completely inhibited by two mAbs 48
and 83, but not by mAb 74.5.2 making these antibodies use-
ful additional tools for inhibition of ligand induced biological
response. Third, whereas residues 204–218, which are recognized
by mAb 74.5.2 constitute the entire β6 structure and part of the
segment of the loop that connects β6 to β7, residues 190–192
and 196–202 form the entire disordered segment of the loop
that connects β5 and β6 sheets in the 3D structure (Erdos and
Sloane, 1962). Since the loops connecting the different β struc-
tures – in particular those connecting β6 to β7 – partially cover
the donut channel, disruption of any of these residues is likely to
disrupt the residues in the channel that form a tight cluster for
efﬁcient binding of mAb 74.5.2, which has been shown to bind
to residues that project into the donut hole (Ghebrehiwet et al.,
2002).
One of the major functions of gC1qR especially on activated or
damaged ECs is its ability to bind HK with high afﬁnity and trigger
the kinin-generating pathway (Joseph et al., 2001a). In plasma,HK
circulates as complex with PK and the two bind to the EC surface
via either gC1qR – which is expressed in excess – or to gC1qR–
cytokeratin 1 complex (Joseph et al., 2004). Bradykinin formation
can then be initiated either by FXII activation – preferentially
bound to the uPAR–cytokeratin complex (Joseph et al., 2004) – or
by secretion of HSP-90 by activated ECs (Joseph et al., 2002).How-
ever, auto activation of FXII can also occur upon binding to gC1qR
(Joseph et al., 2001b, 2009; Shariat-Madar et al., 2002). Although
BK generation can be achieved in solution when HK, PK, and FXII
are mixed together and left to incubate for hours, the addition of
thephysiological receptor,gC1qR,or kaolin accelerates this process
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FIGURE 4 | Dose-dependent binding of gC1qR Δmutants to fixed
U937 cells. U937 cells were ﬁrst attached to 96-well microtiter plates
using poly-l-Lysine and ﬁxed as described (Kennet, 1984; Ghebrehiwet
et al., 1996). The cells were then reacted with biotinylated gC1qR wild
type (WT) or gC1qR deletion mutants (Δ) mutants. After incubation,
the plate was developed by sequential addition of alkaline
phosphatase conjugated streptavidin followed by pNPP. Each data
point is a mean of two experiments run in duplicates and compares
the binding ofWT gC1qR with gC1qRΔ mutants at two
concentrations: 1 and 2.5μg/ml. The ﬁgure in the inset is a
dose-dependent binding ofWT from which the optimal
concentration(s) to be used was determined.
FIGURE 5 | Flow cytometric analysis of gC1qR and deletion mutants.
Biotinylated gC1qR or gC1qR mutants were ﬁrst incubated with U937 cells
(106/ml), and the bound proteins revealed by incubation with a predetermined
dilution of Alexa-488 conjugated streptavidin, ﬁxed by suspension in 4%
paraformaldehyde and then subjected to analysis by ﬂow cytometry. The
ﬁgure is a representative of two such experiments.
from hours to minutes. The function of gC1qR on the cell surface
is likely to be potentiated by either a conformational change upon
ligand binding or the presence of other partner molecules (uPAR
and cytokeratin 1). Regardless, the above experiments prove that
BK can be generated in the presence of soluble gC1qR. This fact
alone gives credence to the postulate that gC1qR,which is secreted
into the pericellular milieu by activated or proliferating cells, can
potentially induce BK generation in the presence of circulating PK,
HK, and FXII,which are recruited to activated ECs (Kaplan, 2004).
This is particularly relevant in infections (Staphylococcus aureus)
or tumor metastasis.
In previous studies (Peterson et al., 1997), we have shown that
recombinant or soluble gC1qR puriﬁed from culture supernatants
of proliferating cells binds to intact U937 cells or ECs. This ﬁnd-
ing prompted us to ask two pertinent questions: why and how does
gC1qR bind to intact cells? Because blockade of both gC1qR and
bradykinin receptor 1 (B1R)–which isnot constitutively expressed
but inducible by IL-1β – abrogates BK-induced angioedema
(Bossi et al., 2009), we hypothesized that secreted gC1qR could
serve as a potential autocrine signal, to induce or suppresses the
expression of cell surface molecules such as B1R. In order to
do so however, the soluble gC1qR must bind to the cell surface
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FIGURE 6 | Immunofluorescence studies. Human Brain microvascular
endothelial cells (HBr-MIVECs) were ﬁrst grown on cover slips and the
attached cells reacted ﬁrst with PBS containing 0.1% BSA and 1% heated
human serum to block unreacted sites, followed by Alexa-488 conjugated
streptavidin or neutravidin. After incubation, the cells were ﬁxed for 10min
with 3.7% (v/v) formalin, and then examined by 3D imaging using
deconvolution microscopy. (A) is non-speciﬁc control and shows the image
of cells reacted with Alexa-conjugated streptavidin (ACS) only. (B–D) show
images of cells that were ﬁrst treated with either biotinylatedWT-gC1q-R,
or deletion mutants 144–148 or 174–180 and then stained with ACS.
through a gC1qR attachment domain presumably on the M-Face
(Ghebrehiwet et al., 2002). While WT gC1qR was able to
bind to U937 cells as expected, four deletion mutants were
identiﬁed that failed to bind: gC1qRΔ144–148, gC1qRΔ174–180,
gC1qRΔ190–192, and gC1qRΔ196–202 (Figure 4). The bind-
ing of these deletion mutants to intact cells was also either
weak or negligible (Figures 5 and 6). Interestingly, domains
141–146 [(PTFDGE) contained in residues 144–148] and 191–
196 (DEVGQE), have extremely high net negative charges and
are not located in all three chains in the crystal structure
and sequences 189–190 and 197–201 are only located in the
A chain. Therefore mutants lacking part or the whole seg-
ment of the two disordered loops – 144–148 connecting β3
to β4 and 191–196 connecting β5 to β6 – are likely to be
critical for ligand binding, structural stability, and/or function.
What is more intriguing is that the nine aa (IKNDDGKKA)
sequence which includes residues174–180 (underlined) found
on the M-face of gC1qR is a highly conserved domain. With
the exception of one or two amino acid substitutions (under-
lined), this domain is identical to sequences found in Trichomonas
vaginalis G3 protein (IKNDDLKKA), Borrelia valaisiana (IKND-
DGKKI ),Borrelia burgdorferi B31 (IKNEDGKKV ), and zebra ﬁsh
(IKNDDGRKA). The relevance of this domain as a cell attach-
ment site and to gC1qR-mediated function is currently being
investigated.
In summary, the present studies not only conﬁrm the rele-
vance of residues 204–218 as an HK site, but also identiﬁed new
sites. This in turn suggests that either HK has multiple sites or
the various HK sites may each contribute residue(s) that form a
ligand binding cluster in space. The gC1qR molecule plays a cen-
tral role in the activation of the kinin system thereby generating
not only BK, but also HKa – a cleavage product of HK – in the
process. While BK is known to induce vascular permeability and
to promote angiogenesis (Guo and Colman, 2005), HKa has been
shown to release cytokines such as TNFα, interleukin IL-1β, IL-6,
and the chemokines IL-8 and MCP-1 from human mononuclear
cells, all of which contribute to inﬂammatory diseases (Khan
et al., 2006). Inasmuch as agents that block gC1qR are likely to
be useful in blocking BK generation, the gC1qR domains identi-
ﬁed in these studies can serve as suitable templates for the design
of either antibody-based or peptide-based therapeutic agents for
the prevention or attenuation of vascular leakage and subsequent
inﬂammation. This rationale is further strengthened by recent ani-
mal model studies that showed: (i) vascular permeability induced
by the attack phase plasma from C1 inhibitor-deﬁcient patients
was prevented by blockade of gC1qR with mAb 74.5.2 (Bossi et al.,
2009), and (ii) blockade of gC1qR – shown previously (Nguyen
et al., 2000) to serve as EC and platelet receptor for protein A –
inhibits adherence of S. aureus to microvascular endothelium
(Sethi et al., 2011).
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